<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046460</url>
  </required_header>
  <id_info>
    <org_study_id>340/12</org_study_id>
    <nct_id>NCT02046460</nct_id>
  </id_info>
  <brief_title>Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD</brief_title>
  <acronym>TREAT-CAD</acronym>
  <official_title>Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stefan Engelter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To demonstrate the non-inferiority of acetylsalicylic acid (ASA) to
      anticoagulant treatment (vitamin K antagonists) in CAD-patients with regard to outcome and
      complication measures.

      Methods: Randomized controlled, open labeled multicenter, non-inferiority trial with blinded
      assessment of outcome events.

      Primary endpoint: Primary composite outcome measure - labeled Cerebrovascular Ischemia, major
      Hemorrhagic events or Death (CIHD) - includes the following efficacy and safety outcome
      measures during the treatment period: (i) occurrence of any stroke*, new acute lesions on
      diffusion weighted MRI (ii) any major extracranial hemorrhage, any symptomatic intracranial
      hemorrhage and any asymptomatic micro- or macrobleeds, (iii) death.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>PROBE-Design: Prospective, randomized, open-label, blinded assessment of end-points.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary composite outcome measure - labeled Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD) -</measure>
    <time_frame>3 months</time_frame>
    <description>CIHD - includes the following efficacy and safety outcome measures during the treatment period: includes the following efficacy and safety outcome measures during the treatment period: (i) occurrence of any stroke (including retinal infarction), new acute lesions on diffusion weighted MRI (ii) any major extracranial hemorrhage, any symptomatic intracranial hemorrhage and any asymptomatic micro- or macrobleeds, (iii) death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>new ischemic strokes (including retinal infarction)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new acute lesions on diffusion-weighted MRI</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any major extracranial hemorrhage</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any symptomatic intracranial hemorrhage</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any asymptomatic micro- or macrobleeds</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any death</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any increase in volume of the vessel wall hematoma at the followup cervical MRI as compared to the baseline MR-scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>independence in activity of daily living (modified Rankin scale 0-2) at 3 months and at 6 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>excellent functional outcome (modified Rankin scale 0,1) at 3 month and at 6 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any TIA (classical definition)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrent cervical artery dissection</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Cervical Artery Dissection</condition>
  <arm_group>
    <arm_group_label>Oral Anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin K-Antagonists, target INR 2.0-3.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiplatelets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetylsalicylic acid, 300mg o.p.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Acetylsalicylic acid, 300mg o.p.d.</description>
    <arm_group_label>Antiplatelets</arm_group_label>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonist</intervention_name>
    <description>Vitamin K-antagonists, target INR 2.0-3.0</description>
    <arm_group_label>Oral Anticoagulation</arm_group_label>
    <other_name>Phenprocoumon, Warfarin, Acenocoumarol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute ischemic or non-ischemic symptoms within 2 weeks

          2. Verification of CAD-diagnosis (carotid and/or vertebral) by MR-techniques (at least
             one):

               -  mural hematoma or

               -  pseudo-aneurysm or

               -  long filiform stenosis or

               -  intimal flap or

               -  double lumen or

               -  occlusion situated more than 2 cm above the bifurcation of the carotid artery,
                  revealing a pseudo aneurysm or a long filiform stenosis after recanalisation.

          3. Written informed consent by patient or next-to-kin

          4. 24h latency period in case of thrombolysis

          5. Age &gt; 18 years by time of inclusion

        Exclusion Criteria:

          1. MR-contraindications (claustrophobia precluding MRI: patients agreeing to undergo MRI
             scanning with mild sedation may be entered into the study)

          2. Contraindications to the use of anticoagulation (vitamin k antagonists, heparin) or
             ASA (according to the Swiss &quot;Arzneimittelkompendium&quot;
             http://www.compendium.ch/search/de or the &quot;Rote Liste&quot; (German centers) or
             &quot;LÃ¦gemiddelstyrelsen - produktresume&quot; for the Danish center
             (https://laegemiddelstyrelsen.dk/da/bivirkninger/find-medicin/produktresumeer/) and
             the judgment of the treating physician)

          3. Pregnancy (Note: for women in child bearing age a pregnancy test has to be done prior
             to study entry)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan T. Engelter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Neurorehab. Felix Platter, University of Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Stroke Center Bispebjerg Hospital Copenhagen, Denmark</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Stroke Center Charite Berlin, Germany</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Stroke Center LMU Munich, Germany</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital, Stroke Center Aarau, Switzerland</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Stroke Center Basel, Switzerland</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Stroke Center Inselspital Berne, Switzerland</name>
      <address>
        <city>Berne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Stroke Center Geneva, Switzerland</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Stroke Center CHUV Lausanne, Switzerland</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital, Stroke Center St. Gallen, Switzerland</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Stroke Center Zurich, Switzerland</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Stefan Engelter</investigator_full_name>
    <investigator_title>Prof. Dr. med., MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Phenprocoumon</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02046460/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

